Products

Once-daily oral GLP-1 pill from Eli Lilly, FDA-approved April 1, 2026 for weight management in adults. Launch self-pay price from $149/month for the lowest…

Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for type 2 diabetes. Not approved for weight management. Official self-pay price not publicly verified (Sept 20,…

Once-weekly tirzepatide injection from Eli Lilly, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Self-pay $299 to $449/month via…

Once-weekly semaglutide injection from Novo Nordisk, FDA-approved for type 2 diabetes and related heart and kidney risk reduction. Not approved for weight management. Self-pay…

Once-daily oral semaglutide tablet from Novo Nordisk, FDA-approved December 2025 for weight management and cardiovascular risk reduction in adults. Self-pay $149 to $299/month by…

Once-weekly semaglutide injection from Novo Nordisk. FDA-approved for chronic weight management, cardiovascular risk reduction and noncirrhotic MASH with fibrosis. Self-pay from $349/month via NovoCare…